Featured Research

from universities, journals, and other organizations

Medication does not help prevent ED following radiation therapy for prostate cancer

Date:
April 1, 2014
Source:
The JAMA Network Journals
Summary:
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study. Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment. An estimated 40 percent of men report ED after radiation therapy, and half of all men use erectile aids following this therapy.

Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA.

Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment. An estimated 40 percent of men report ED after radiation therapy, and half of all men use erectile aids following this therapy. Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, but its role as a preventive agent has not been determined, according to background information in the article.

Thomas M. Pisansky, M.D., of the Mayo Clinic, Rochester, Minn., and colleagues with the Radiation Therapy Oncology Group, randomly assigned 242 men with prostate cancer to receive tadalafil (5 mg) or placebo daily for 24 weeks starting with radiation therapy (either with external radiotherapy [63 percent] or brachytherapy [37 percent]). The study was conducted at 76 sites in the United States and Canada; participants were recruited between November 2009 and February 2012, with follow-up through March 2013.

Between weeks 28 and 30 after the start of radiation therapy, among evaluable participants, 79 percent who received tadalafil retained erectile function compared with 74 percent who received placebo, an absolute difference of 5 percent. A significant difference between groups was also not observed at 1 year (72 percent vs 71 percent). Tadalafil was not associated with improved overall sexual function or satisfaction, and partners of men assigned tadalafil noted no significant effect on sexual satisfaction.

"These findings do not support the scheduled once-daily use of tadalafil to prevent ED in men undergoing radiotherapy for localized prostate cancer," the authors write.

They add that alternative strategies to prevent ED in this context appear warranted, including different dosing or further refinements of radiation therapy delivery methods.


Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas M. Pisansky, Stephanie L. Pugh, Richard E. Greenberg, Nadeem Pervez, Daniel R. Reed, Seth A. Rosenthal, Rex B. Mowat, Adam Raben, Mark K. Buyyounouski, Lisa A. Kachnic, Deborah W. Bruner. Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer. JAMA, 2014; 311 (13): 1300 DOI: 10.1001/jama.2014.2626

Cite This Page:

The JAMA Network Journals. "Medication does not help prevent ED following radiation therapy for prostate cancer." ScienceDaily. ScienceDaily, 1 April 2014. <www.sciencedaily.com/releases/2014/04/140401162154.htm>.
The JAMA Network Journals. (2014, April 1). Medication does not help prevent ED following radiation therapy for prostate cancer. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/04/140401162154.htm
The JAMA Network Journals. "Medication does not help prevent ED following radiation therapy for prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2014/04/140401162154.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins